Court Boots Whistleblower Suit Accusing Bayer of Deceptive Marketing of Baycol

A federal trial court in Minnesota July 19 dismissed a whistleblower suit against Bayer Corp. over allegedly false claims that state and federal health programs paid for Bayer’s cholesterol drug Baycol (cerivastatin) (In re Baycol Products Litigation, D. Minn., 08-cv-05758, 7/19/12).

Granting Bayer’s motion to dismiss the whistleblower’s second amended complaint (SAC), Chief Judge Michael J. Davis of the U.S. District Court for the District of Minnesota said the complaint, brought by Laurie Simpson, a former market research manager at Bayer, failed to meet the heightened standard required for pleading claims under the False Claims Act.

“[P]articularized allegations ...